



ACC.19™

68th Annual Scientific Session & Expo

AG10 Consistently Stabilizes Transthyretin to a High Level in Both Wild Type and Mutant Amyloid Cardiomyopathy: Responder Analyses from a Phase 2 Clinical Trial

Heitner, Stephen B; Falk, Rodney H; Grogan, Martha; Jacoby, Daniel; Judge, Daniel P; Maurer, Mathew S; Selby, Van N; Shah, Sanjiv J; Witteles, Ronald M; Rao, Satish; Sinha, Uma; and Fox, Jonathan C




**NEW
ORLEANS**
MARCH 16 - 18
2019

Stephen Heitner presenting on behalf of
the AG10 Phase 2 study investigators



Original Investigations

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy

Daniel P. Judge MD^a, Rodney H. Falk MD^b, Mathew S. Maurer MD^c, Sanjiv J. Shah MD^d, Ronald M. Witteles MD^e, Martha Grogan MD^f, Van N. Selby MD^g, Daniel Jacoby MD^h, Mazen Hanna MDⁱ, Jose Natvi-Nicolau MD^j, Jignesh Patel MD^k, Satish Rao PhD^l, Uma Sinha PhD^l, Cameron W. Turtle DPhil^l, Jonathan C. Fox MD, PhD^l, Stephen B. Heitner MD^m   

^a Department of Medicine, Medical University of South Carolina, Charleston, South Carolina

^b Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts

^c Columbia University Irving Medical Center, New York, NY

^d Northwestern University Feinberg School of Medicine, Chicago, IL

^e Stanford University Medical Center, Stanford, CA

^f Mayo Clinic, Rochester MN

^g University of California, San Francisco, San Francisco, CA

^h Yale University Medical Center, New Haven, CT

ⁱ Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH

^j University of Utah Health, Salt Lake City, UT

^k Cedars-Sinai Medical Center, Los Angeles, CA

^l Eidos Therapeutics, Inc., San Francisco CA

^m Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon

Received 8 February 2019, Revised 26 February 2019, Accepted 9 March 2019, Available online 15 March 2019.

 Show less

<https://doi.org/10.1016/j.jacc.2019.03.012>

Under a Creative Commons license

Get rights and content

 open access

ATTR Cardiomyopathy Clinical Presentation

Clinical presentation

- ATTR-CM is an infiltrative, restrictive cardiomyopathy resulting from deposition of wild-type or mutant TTR amyloid in the heart
- Cardiac amyloid deposition can lead to edema, interventricular wall thickening, and diastolic heart failure

Growing patient population

Non-invasive diagnosis by Tc-PYP scans increasingly finding ATTR-CM patients “hiding in plain sight”:

- 13-19% of HFpEF patients¹⁻³
- 16% of patients undergoing TAVR⁴
- 5% of patients with presumed hypertrophic cardiomyopathy⁵
- 8% of patients undergoing bilateral carpal tunnel release surgery⁶

ATTR-CM = Transthyretin Amyloid Cardiomyopathy; TTR = Transthyretin; Tc-PYP = Technetium pyrophosphate; HFpEF = Heart Failure with Preserved Ejection Fraction; TAVR = Transcatheter Aortic Valve Replacement

1) Gonzalez-Lopez, E. et al. Eur Heart J., 2015, 36(38):2585-94; 2) Mohammed, S.F. et al. JACC: Heart Failure, 2014, 2(2):113-22; 3) Horvath, S.A. et al. Circulation, 2018, 138:A16205; 4) Castano, A. et al. Eur Heart J., 2017, 38(38):2879-87; 5) Damy, T. et al. Eur Heart J., 2015, 37:1826-34; 6) Sperry, B.W. et al. JACC, 2018, 72(17):2040-50



Disease Mechanism and Therapeutic Hypothesis

Native TTR circulates in blood as a tetramer

Dissociation into monomers initiates pathogenesis

Monomers aggregate, causing disease


Disease mechanism



~130 known destabilizing mutations



Therapeutic hypothesis



T
T119M
stabilizing
mutation


AG10 stabilizes TTR tetramers and increases serum TTR; unique binding mode mimics the T119M stabilizing mutation



ACC.19

Phase 2 Study Design

Randomized, double-blind, placebo controlled, multi-center study of AG10 in ATTR-CM patients



- **Key inclusion criteria:** ≥ 1 prior hospitalization for heart failure or clinical evidence of heart failure, confirmed ATTR by scan or biopsy, NYHA Class II/III
- **Primary endpoint:** safety and tolerability
- **Secondary endpoints:** Pharmacokinetics, TTR stabilization as measured by FPE and Western blot, serum TTR concentration
- **Open label extension (ongoing):** safety and tolerability, cardiac biomarkers, echocardiographic measurements

NYHA = New York Heart Association; FPE = Fluorescent Probe Exclusion



ACC.19

Subject Demographics

Characteristic	ATTRwt-CM N = 35	ATTRm-CM N = 14	Total N = 49
Age, mean (range)	74 (60 - 85)	73 (60 - 86)	74 (60 - 86)
Male, n (%)	33 (94%)	12 (86%)	45 (92%)
NYHA Class III, n (%)	10 (29%)	4 (29%)	14 (29%)
Race, n (%)			
White	31 (89%)	4 (29%)	35 (71%)
Black	2 (6%)	8 (57%)	10 (20%)
Asian	1 (3%)	0 (0%)	1 (2%)
Other	1 (3%)	2 (14%)	3 (6%)
TTR (mg/dL) ¹	23.7 ± 4.7	17.5 ± 4.6*	22.0 ± 5.4
NT-proBNP (pg/mL) ²	2612 ± 2108	5258 ± 3423	3368 ± 2789
Troponin I (ng/mL) ³	0.09 ± 0.05	0.34 ± 0.38 [†]	0.16 ± 0.22
Interventricular Wall Thickness (cm)	1.74 ± 0.30	1.75 ± 0.33	1.74 ± 0.30


1 TTR normal range = 20 – 40 mg/dL; * TTR concentration not available at baseline for one ATTRm-CM subject

2 NT-proBNP normal range = 0 – 449 pg/mL


3 Troponin I normal range = 0 – 0.02 ng/mL; [†] Troponin I not available at baseline for one ATTRm-CM subject

ATTRm-CM Genotype

N=14




Near-Complete TTR Stabilization Demonstrated by AG10 in Both Wild-Type and Mutant Subjects



* $p < 0.05$ compared to corresponding placebo groups



Increase in Serum TTR Concentration Observed in ATTRwt and ATTRm Subjects Treated with AG10




Note: Serum TTR concentration not available at baseline for one ATTRm-CM subject; and at Day 28 for one ATTRwt-CM subject and two ATTRm-CM subjects

* $p < 0.05$ compared to corresponding placebo groups



Treatment with AG10 restored serum TTR concentrations to normal range in all subjects



¹ Normal reference range for serum TTR 20-40 mg/dL (3.6-7.3 μ M)

Note: Serum TTR concentration not available at baseline for one ATTRm-CM subject and at Day 28 for one ATTRm-CM subject




Conclusions

- In a cohort of patients with either mutant or wild-type ATTR-CM, AG10 demonstrated near-complete stabilization of TTR
- At study entry, 33% of ATTRwt-CM and 80% of ATTRm-CM subjects had serum TTR below normal
- Treatment with 800 mg AG10 bid restored serum TTR levels to normal range
 - Increased serum TTR from baseline by 35% and 84% at Day 28 in ATTRwt-CM and ATTRm-CM subjects, respectively
- These results support further development of AG10 in both the ATTRwt-CM and ATTRm-CM populations



ATTRIBUTE-CM Phase 3 Study Schematic



¹ As local standard of care evolves, concomitant use of approved, indicated therapies may be allowed

^{99m}Tc = Technetium labeled pyrophosphate (PYP) or bisphosphonate (e.g., DPD); 6MWD = Six minute walk distance; CV hosp = cardiovascular-related hospitalizations

